Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125528601 | 12552860 | 1 | I | 20160704 | 20160713 | 20160713 | EXP | PHHY2016JP094500 | SANDOZ | 69.00 | YR | F | Y | 0.00000 | 20160713 | OT | JP | JP |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125528601 | 12552860 | 1 | PS | IRINOTECAN | IRINOTECAN | 1 | Unknown | 60 MG/M2, CYCLIC | 90137 | 60 | MG/M**2 | ||||||||
125528601 | 12552860 | 2 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | 60 MG/M2, CYCLIC | 0 | 60 | MG/M**2 | ||||||||
125528601 | 12552860 | 3 | C | MITOTANE | MITOTANE | 1 | Unknown | 3 G, QD | 0 | 3 | G | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125528601 | 12552860 | 1 | Neuroendocrine carcinoma metastatic |
125528601 | 12552860 | 2 | Neuroendocrine carcinoma metastatic |
125528601 | 12552860 | 3 | Cushing's syndrome |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125528601 | 12552860 | DE |
125528601 | 12552860 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125528601 | 12552860 | Disease recurrence | |
125528601 | 12552860 | Drug effect incomplete | |
125528601 | 12552860 | Drug ineffective | |
125528601 | 12552860 | Haematotoxicity | |
125528601 | 12552860 | Hepatic failure |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |